Strategic Acquisition Ze vacor has recently become part of a larger platform through Curium Pharma acquisition, indicating potential for cross-sell of radiopharmaceuticals, imaging services, and educational offerings to Curium’s expanded customer base and distribution network.

Integrated Manufacturing With a 70 MeV cyclotron and multi-unit synthesis setup nearing completion in Noblesville, Zevacor can position itself as a reliable supplier for clinical and research radioisotopes, offering scalable production for partner projects and early-stage trials.

Full-Service Radiopharma Ze vacor provides both manufacturing of PET/SPECT radiopharmaceuticals and custom radiolabeling services, creating opportunities to upsell bundled imaging agents, labeling services, and on-site or rapid-turnaround projects for pharma and biotech customers.

Non-Profit Backbone As part of Illinois Health and Science, Zevacor’s non-profit parent may align with grant-supported collaborations, research partnerships, and cost-effective pilot programs that attract academic and government-funded projects seeking radiopharmaceutical capabilities.

SMB Focused Scale With a lean team and revenue in the mid single-digit millions, there’s a clear opportunity to offer scalable, high-touch solutions, such as managed services, regulatory/compliance support, and flexible contract manufacturing arrangements tailored to small and mid-sized pharma and biotech customers.